A GP guide to managing vitiligo
Vitiligo is linked to significant comorbidity, but early diagnosis and treatment can make a substantial difference to disease progression and quality of life
Vitiligo is a common, acquired depigmentation disorder, affecting 0.5-2% of the global population.1
It has a similar prevalence to psoriasis, which affects just over 2% of Australians.2
Prevalence varies geographically, with reported rates as low as 0.093% in China and as high as 8.8% in India.3,4
Women are more likely to present for treatment than men, and peak age onset is in those aged 10-30 years.1
